Private Advisor Group LLC Acquires 6,987 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Private Advisor Group LLC increased its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 230.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,017 shares of the company’s stock after purchasing an additional 6,987 shares during the period. Private Advisor Group LLC’s holdings in TransMedics Group were worth $1,509,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Charles Schwab Investment Management Inc. increased its holdings in TransMedics Group by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 253,517 shares of the company’s stock worth $20,010,000 after purchasing an additional 4,343 shares in the last quarter. Envestnet Portfolio Solutions Inc. raised its position in TransMedics Group by 68.8% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 6,261 shares of the company’s stock valued at $494,000 after buying an additional 2,551 shares during the last quarter. Principal Financial Group Inc. lifted its stake in TransMedics Group by 21.3% in the 4th quarter. Principal Financial Group Inc. now owns 21,929 shares of the company’s stock valued at $1,731,000 after acquiring an additional 3,858 shares in the last quarter. Level Four Advisory Services LLC acquired a new position in TransMedics Group during the 4th quarter worth approximately $471,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of TransMedics Group during the 4th quarter worth approximately $889,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at TransMedics Group

In related news, insider Nicholas Corcoran sold 10,000 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the transaction, the insider now owns 21,105 shares in the company, valued at approximately $3,714,902.10. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $145.17, for a total value of $1,252,091.25. Following the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at $8,948,714.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Nicholas Corcoran sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the transaction, the insider now directly owns 21,105 shares in the company, valued at $3,714,902.10. The disclosure for this sale can be found here. In the last 90 days, insiders sold 52,622 shares of company stock worth $8,327,633. 7.00% of the stock is owned by insiders.

Analysts Set New Price Targets

TMDX has been the subject of several recent research reports. Morgan Stanley increased their target price on shares of TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Cantor Fitzgerald initiated coverage on TransMedics Group in a report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price objective for the company. Oppenheimer upped their target price on TransMedics Group from $125.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. Canaccord Genuity Group raised their price target on TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Finally, Stephens boosted their price target on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, TransMedics Group has an average rating of “Moderate Buy” and an average price target of $171.44.

TransMedics Group Stock Performance

TMDX opened at $151.42 on Friday. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. TransMedics Group, Inc. has a 12-month low of $36.42 and a 12-month high of $177.37. The business has a 50 day moving average of $154.20 and a 200-day moving average of $126.66. The stock has a market cap of $5.05 billion, a price-to-earnings ratio of -445.35 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.14. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The business had revenue of $114.30 million during the quarter, compared to the consensus estimate of $98.84 million. During the same quarter last year, the firm posted ($0.03) EPS. The company’s quarterly revenue was up 117.7% on a year-over-year basis. On average, equities research analysts expect that TransMedics Group, Inc. will post 1.23 earnings per share for the current year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.